Wildy logo
(020) 7242 5778

Wildy’s Book News

Book News cover photo

Vol 22 No 4 April/May 2017

Book of the Month

Cover of Whistleblowing: Law and Practice

Whistleblowing: Law and Practice

Price: £175.00

Pupillage & Student Offers

Special Discounts for Pupils, Newly Called & Students

Read More ...

Secondhand & Out of Print

Browse Secondhand Online


UK Public Holiday May 2017

Wildy's will be closed on Monday 29th May and will re-open on Tuesday 30th May.

Online book orders received during the time we are closed will be processed as soon as possible once we re-open on Tuesday.

As usual Credit Cards will not be charged until the order is processed and ready to despatch.

Any non-UK eBook orders placed after 5pm on the Friday 26th May will not be processed until Tuesday 30th May. UK eBook orders will be processed as normal.

Hide this message

Patenting the Recombinant Products of Biotechnology and Other Molecules

Image not available lge

ISBN13: 9789041106988
ISBN: 9041106987
Published: October 1997
Publisher: Kluwer Law International
Format: Hardback
Price: £121.00

This work examines the requirements for patentability in the context of biotechnology, with a special focus on the non-obviousness requirement. It analyzes non-obviousness as applied to biotechnology molecular products via a review of the relevant case law. The work begins with a typology of recombinant inventions, useful in determining ultimate non-obviousness and patentability. It distinguishes three categories of recombinant products: (1) ""Translation"" inventions, obtained by entering a known molecular information into a known process, (2) ""Molecular modification"" products, obtained by modifying prior art molecules, and (3) ""Combination"" inventions, obtained by combining several known functional molecular units.;Recognizing the risk that many translation inventions will be considered obvious upon maturation of the underlying technology, the author examines possible alternatives for protection. The author critiques and ultimately rejects the idea of lowering the non-obviousness standard, elected by the Federal Circuit in In re Deuel. The work describes several current examples of sui generis intellectual property rights and also examines a ""no action"" scenario, emphasizing that the rapid changes occurring in biotechnology might ultimately make the current problem obsolete.;The text also addresses broader issues such as the growing secrecy in basic science and its link to the disappearance of a clear distinction between basic and applied research. Patent law practitioners, inventors and researchers in the biotech world, and their advisors should appreciate this detailed, analysis.

Image not available lge
Patent law primer; recombinant products and the standard for obviousness - a typology; in re Deuel - the Federal circuit and ""translation"" DNAs; generalization of a concept - other biotechnology products are ""translation"" inventions; consequences and remedies.